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The blue and red lines represent the observed and simulated data, respectively; the solid lines represent the 50 th percentile, with the dashed lines representing the 5 th and 95 th percentiles; while the open circles represent the observed data points, and the orange dotted horizontal line indicates the lower limit of quantification (LLOQ).
Reference Ranges for Risperidone & Paliperidone Plasma Concentrations

Population PK Model for Oral Risperidone
The following modifications were undertaken during the update of the population PK model for oral risperidone:
• Inclusion of an additional parameter describing the apparent clearance of risperidone for unknown concomitant administration of carbamazepine.
• A joint estimate of the apparent clearance of paliperidone in subjects where concomitant administration or absence of concomitant carbamazepine was known.
• Inclusion of an additional parameter describing the apparent clearance of paliperidone where concomitant administration of carbamazepine was unknown.
• Removal of the study effect that allowed for differing proportions of intermediate and extensive CYP2D6 metabolisers in single dose trials.
• Inclusion of age as a covariate effect on the apparent clearance of risperidone, which increased linearly to an estimated age cut-point, and declined thereafter in a non-linear manner. (1-FR1-FR2) ALAG2 = absorption lagtime of the second pathway; ALAG6 = absorption lagtime of the third pathway; CL/F = apparent clearance; F = apparent bioavailability; FR1 = fraction of dose absorbed via the first pathway; FR2 = fraction of dose absorbed via the second pathway; KTR1 = first-order absorption rate constant of the first pathway; KTR2 = transit absorption rate constant of the second pathway; KTR3 = transit absorption rate constant of the third pathway; Vc/F = apparent central volume of distribution. 
